期刊文献+
共找到10篇文章
< 1 >
每页显示 20 50 100
论建立动物药剂学科的现实性 被引量:3
1
作者 谢麟 《四川畜牧兽医》 2000年第4期30-30,32,共2页
现代动物药品业、动物养殖业和动物临床药学的发展 ,急需建立系统的动物药剂学科 ,才能适应当前动物药品从生产、研究、开发、应用、质量监督到培养人才的需要。本文论述了动物药剂科技的历史与现状 ,介绍《动物药剂技术手册》 。
关键词 技术手册 动物药剂学科 学科成立 《动物药剂》
在线阅读 下载PDF
《动物药剂的应用与制作科技全书》
2
《中国兽药杂志》 2004年第6期47-47,共1页
关键词 《动物药剂的应用与制作科技全书》 药剂品种 饲料添加药剂 书评
在线阅读 下载PDF
A Self-assembled Nanomicelle for Realizing Tumor Photodynamic Therapy via Increasing Drug Accumulation and Prolonging Retention Time
3
作者 AN Yaolong LI Zi-Heng WU Fu-Gen 《高等学校化学学报》 北大核心 2025年第1期106-116,共11页
A nanomicelle(denoted as TPGS/Ppa)was fabricated via the coassembly of the amphiphilic D-α-tocopheryl polyethylene glycol 1000 succinate(TPGS)and the hydrophobic photosensitizer pyropheophorbide a(Ppa)for photodynami... A nanomicelle(denoted as TPGS/Ppa)was fabricated via the coassembly of the amphiphilic D-α-tocopheryl polyethylene glycol 1000 succinate(TPGS)and the hydrophobic photosensitizer pyropheophorbide a(Ppa)for photodynamic therapy(PDT).The obtained nanomicelle possessed a spherical structure with a diameter of(18.0±2.2)nm and a zeta potential of approximately -18 mV.Besides,the nanomicelle exhibited excellent photostability,biocompatibility,and phototoxicity,and could effectively reach the tumor region via the enhanced permeability and retention effect.Additionally,it could be found that the TPGS/Ppa nanomicelle exhibited higher phototoxicity against 4T1 murine mammary cancer cells than free Ppa.In the 4T1 tumor-bearing mouse model,the nanomicelle showed an excellent antitumor therapeutic effect.This study develops a new type of photodynamic nanomicelle TPGS/Ppa,which can increase the accumulation of drugs and prolong their tumor retention time,providing a feasible strategy for realizing the delivery of small-molecule hydrophobic drugs and tumor PDT. 展开更多
关键词 Photodynamic therapy Nanodrug PHOTOSENSITIZER D-α-Tocopheryl polyethylene glycol 1000 succinate Cell apoptosis
在线阅读 下载PDF
Effect of Sinai San decoction on the development of non-alcoholic steatohepatitis in rats 被引量:6
4
作者 QiZhang YanZhao +1 位作者 Deng-BenZhang Li-JunSun 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第9期1392-1395,共4页
AIM: To explore the effect of Sinai san decoction on the development of non-alcoholic steatohepatitis induced by CCL4 combined with a fat-rich diet in rats.METHODS: Twenty-seven Sprague-Dawley rats were divided into t... AIM: To explore the effect of Sinai san decoction on the development of non-alcoholic steatohepatitis induced by CCL4 combined with a fat-rich diet in rats.METHODS: Twenty-seven Sprague-Dawley rats were divided into three groups randomly: control group (n = 9),model group (n = 9) and treatment group (n = 9). The rats of model group and treatment group were given small dosage of CCL4 combined with a fat-rich diet, andthose of control group were given normal diet. After four weeks of fat-rich diet feeding, the rats of treatment group were given Sinai san decoction. The serum levels of aminotransferase and lipid were measured, and the pathology of livers was observed by HE staining after the rats were sacrificed at eight weeks.RESULTS: The rats' livers presented the pathology of steatosis and inflammation with higher serum levels of ALT and AST in the model group. In the treatment group the serum ALT and AST levels decreased significantly and were close to the control group. The hepatic inflammation scores also decreased markedly, but were still higher than those of control group. And the degree of hepatocyte steatosis was similar to that of model group.CONCLUSION: Sinai san decoction may ameliorate the hepatic inflammation of rats with steatohepatitis induced by small dosage of CCL4 combined with a fat-rich diet,but does not prevent the development of hepatocyte steatosis. 展开更多
关键词 Sinai san decoction Fatty liver Non-alcoholic steatohepatitis Traditional Chinese Medicine
在线阅读 下载PDF
Impact of release characteristics of sinomenine hydrochloride dosage forms on its pharmacokinetics in beagle dogs 被引量:5
5
作者 Jin Sun Jie-Ming Shi +5 位作者 Tian-Hong Zhang Kun Gao Jing-Jing Mao Bing Li Ying-Hua Sun Zhong-Gui He 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第29期4547-4551,共5页
AIM: To investigate the effect of release behavior of sustained-release dosage forms of sinomenine hydrochloride (SM·HCl) on its pharmacokinetics in beagle dogs. METHODS: The in vitro release behavior of two ... AIM: To investigate the effect of release behavior of sustained-release dosage forms of sinomenine hydrochloride (SM·HCl) on its pharmacokinetics in beagle dogs. METHODS: The in vitro release behavior of two SM·HCl dosage forms, including commercial 12-h sustained-release tablets and 24-h sustained-release pellets prepared in our laboratory, was examined. The two dosage forms were orally administrated to beagle dogs, and then the in vivo SM.HCI pharmacokinetics was investigated and compared. RESULTS: The optimal SM·HCl sustained-release formulation was achieved by mixing slow- and rapidrelease pellets (9:1, w/w). The SM·HCl release profiles of the sustained-release pellets were scarcely influenced by the pH of the dissolution medium. Release from the 12-h sustained-release tablets was markedly quicker than that from the 24-h sustained-release pellets, the cumulative release up to 12-h was 99.9% vs68.7%. From a pharmacokinetic standpoint, the 24-h SM.HCI sustainedrelease pellets had longer tmax and lower Cmax compared to the 12-h sustained-release tablets, the tmax being 2.67±0.52 h vs 9.83±0.98 h and the Cmax being 1334.45±368.76 ng/mL vs 893.12±292.55 ng/mL, respectively. However, the AUC0-tn of two SM·HCl dosage forms was comparable and both preparations were statistically bioequivalent. Furthermore, the two preparations had good correlations between SM·HCl percentage absorption in vivoand the cumulative percentage release in vitro. CONCLUSION: The in vitro release properties of the dosage forms strongly affect their pharmacokinetic behavior in vivo. Therefore, managing the in vitro release behavior of dosage forms is a promising strategy for obtaining the optimal in vivo pharmacokinetic characteristics and safe therapeutic drug concentration-time curves. 展开更多
关键词 SINOMENINE Release behavior PHARMACOKINETICS PELLETS
在线阅读 下载PDF
Effect of Jianweiyuyang granule on gastric ulcer recurrence and expression of VEGF mRNA in the healing process of gastric ulcer in rats 被引量:6
6
作者 Xing-Ping Dai Jia-Bang Li +3 位作者 Zhao-Qian Liu Xiang Ding Cheng-Hui Huang Bing Zhou 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第35期5480-5484,共5页
AIM: To investigate the effect of Jianweiyuyang (JWYY)granule on gastric ulcer recurrence and its mechanism in the treatment of gastric ulcer in rats.METHODS: Gastric ulcer in rats was induced according to Okeba's... AIM: To investigate the effect of Jianweiyuyang (JWYY)granule on gastric ulcer recurrence and its mechanism in the treatment of gastric ulcer in rats.METHODS: Gastric ulcer in rats was induced according to Okeba's method with minor modification and the recurrence model was induced by IL-1β. The expression of vascular endothelial growth factor mRNA (VEGF mRNA) was examined by reverse transcription polymerase chain reaction in gastric ulcer and microvessel density (MVD) adjacent to the ulcer margin was examined by immunohistochemistry.RESULTS: MVD was higher in the JWYY treatment group (14.0±2.62) compared with the normal, model and ranitidine treatment groups (2.2±0.84, 8.8±0.97, 10.4±0.97) in rats (P<0.01). The expression level of VEGF mRNA in gastric tissues during the healing process of JWYY treatment group rats significantly increased compared with other groups (normal group: 0.190±0.019, model group: 0.642±0.034,ranitidine group: 0.790±0.037, P<0.01).CONCLUSION: JWYY granules can stimulate angiogenesis and enhance the expression of VEGF mRNA in gastric ulcer rats. This might be the mechanism for JWYY accelerating the ulcer healing, and preventing the recurrence of gastric ulcer. 展开更多
关键词 Jianweiyuyang granule Gastric ulcer VEGF mRNA
在线阅读 下载PDF
Solubilities of Cimaterol and Mabuterol in SF-CO_2 被引量:1
7
作者 李淑芬 《Chinese Journal of Chemical Engineering》 SCIE EI CAS CSCD 2000年第1期27-32,共6页
The solubilities of two β-agonists, cimaterol and mabuterol, in supercritical carbon dioxide (SF-CO2) were measured by a recirculating method at temperatures of 40℃ and 60℃ and pressures between 9 MPa to 49 MPa.The... The solubilities of two β-agonists, cimaterol and mabuterol, in supercritical carbon dioxide (SF-CO2) were measured by a recirculating method at temperatures of 40℃ and 60℃ and pressures between 9 MPa to 49 MPa.The compounds exhibit very limited solubilities in the range of 10^-5 to 10^-7 (mole fraction). Cimaterol has a higher solubility than that of mabuterol. The experimental data of solubility were correlated by four density-based models.The correlation accuracy highly depends on the system investigated, which is mainly determined by the density ranges and temperature. 展开更多
关键词 Β-AGONISTS cimaterol mabuterol supercritical carbon dioxide SOLUBILITY
在线阅读 下载PDF
Effect of Synthetic Leucopyrokinin Analog [D-AlaS]-[2-8]-Leucopyrokinin ([D-AlaS]-[2-8]-LPK) on Opioid-lnduced Analgesia in Rats
8
作者 Andrzej Plech Monika Rykaczewska-Czerwifiska +1 位作者 Adam Sipifiski Danuta Konopifiska 《Journal of Agricultural Science and Technology(A)》 2012年第5期682-689,共8页
The study was undertaken in order to evaluate effect of synthetic insect neuropeptide leucopyrokinin analog, [D-Ala5]-[2-8]-LPK, on analgesia induced by selective agonists of/a-, 6- and l〈-opioid receptors. The study... The study was undertaken in order to evaluate effect of synthetic insect neuropeptide leucopyrokinin analog, [D-Ala5]-[2-8]-LPK, on analgesia induced by selective agonists of/a-, 6- and l〈-opioid receptors. The study was performed on male Wistar rats, which a week before the experiments were implanted with polyethylene cannulas into the lateral brain ventricle (icv). Effect of prior administration of [D-Ala5]-[2-8]-LPK on analgesia induced in rats by next icv administration of equimolar dose of μ-, δ- and -opioid agonists: DAMGO, DPDPE and GR fumarate respectively, was evaluated. Antinociceptive effect was determined in rats by the test of the tail immersion. It was found that two doses of 5 and 10 nmols icv of [D-AlaS]-[2-8]-LPK inhibited analgesia in rats by equimolar doses of DAMGO. This analog also transiently (only in two time intervals) and in one dose of 10 nmols inhibited analgesia induced in rats by icv administration of equimolar DPDPE dose of 10 nmols icv. Obtained results indicate that [D-AlaS]-[2-8]-LPK inhibits antinociceptive effect of DAMGO and in part of DPDPE, i.e. mainly antagonized ~t-opioid receptors. These results correspond with results of our previous study that selective antagonists of μ- and δ-opioid receptors blocked antinociceptive effect of synthetic insect neuropeptide leucopyrokinin and of it active analog [2-8]-leucopyrokinin. We regard that [D-AIaS]-[2-8]-LPK, the first discovered antagonist of leucopyrokinin may be a useful as a probable tool substance in the study of biological effects of insect-derived peptides either in invertebrates or in mammals. 展开更多
关键词 [D-Ala5]-[2-8]-leucopyrokinin opioid receptors agonists antinociceptive effect rats.
在线阅读 下载PDF
Pharmacokinetics of diclazuril after oral administration of clinical doses to rabbits 被引量:1
9
作者 胡连栋 刘慈 徐文 《Journal of Chinese Pharmaceutical Sciences》 CAS 2009年第3期273-277,共5页
The purpose of this study was to evaluate the pharmacokinetic parameters and bioavailability of the solid dispersion formulation of diclazuril after oral administration in rabbits in comparison with its known premix f... The purpose of this study was to evaluate the pharmacokinetic parameters and bioavailability of the solid dispersion formulation of diclazuril after oral administration in rabbits in comparison with its known premix form with feed additive.Plasma concentrations were determined by high-performance liquid chromatography(HPLC).The areas under the plasma concentration curves(AUC0-∞) of diclazuril in solid dispersion and premix were 247.8±18.1μg/h/mL and 145.4±12.6μg/h/mL,respectively. The Cmax of diclazuril in solid dispersion and premix were 33.72±4.75 μg/mL and 10.42±3.4μg/mL, respectively, The t1/2 were 9.53±1.37 and 9.23±1.20 min, respectively. The oral bioavailability of drug solid dispersion was 1.7-fold higher than that of premix. From these data we concluded that diclazuril solid dispersion may be used as a potential anticoccidial preparation. 展开更多
关键词 DICLAZURIL RABBITS PHARMACOKINETICS Oral administration High-performance liquid chromatography
原文传递
Determination of dabigatran in dog plasma by LC-MS/MS and its application to a pharmacokinetic study of dabigatran etexilate nanosuspension
10
作者 从双晨 张媛媛 +7 位作者 雷冏茜 宋茂远 张文茜 彭光华 殷梦雅 李佳佳 王佳星 李馨儒 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2017年第8期589-594,共6页
In this study, a sensitive and rapid LC-MS/MS method was developed and validated to determine dabigatran in plasma of beagle dogs after oral administration of dabigatran etexilate nanosuspension (DABE-NS). The analy... In this study, a sensitive and rapid LC-MS/MS method was developed and validated to determine dabigatran in plasma of beagle dogs after oral administration of dabigatran etexilate nanosuspension (DABE-NS). The analytes (dabigatran) and sertraline hydrochloride (internal standard, IS) were separated on a Kromasil C18 column using gradient elution consisting of methanol and formate buffer at a flow rate of 0.4 mL/min in 20 min. Detection and quantitation were carded out by multiple reaction monitoring following the transitions: m/z 472.17→289.07 and 305.98→275.00 for dabigatran and IS at positive ion mode, respectively. The calibration curves were linear from 1.0 to 500.0 ng/mL for dabigatran with r = 0.9995. The accuracy of each analyte ranged from 94.8% to 107.1%, and the precision was within 6%. Besides, this method was successfully applied in the investigation of the pharmacokinetic profile of dabigatran in beagle dogs after oral administration of DABE-NS. The maximum concentration and the areas under curves of dabigatran for DABE-NS were significantly higher than those of control formulation, indicating improved oral absorption. 展开更多
关键词 DABIGATRAN Dabigatran etexilate LC-MS/MS NANOSUSPENSION PHARMACOKINETICS
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部